Skip to main content

Maravai Lifesciences Holdings, Inc Investor Event Transcript, Nov 17, 2026

Maravai Lifesciences Holdings, Inc. (MRVI)

Maravai Lifesciences reported third-quarter revenue growth of 10%, with mRNA up 28% and Cygnus up 8%. Management said the $14 million and change in first-quarter COVID-related clean cap revenue should be kept out of guidance. AI summary

Investor Event Transcript 2026-11-17 For: 2026-12-31
Added on November 17, 2026

Conference Transcript - MRVI 2026-11-17

Matthew Stanton, Analyst — Jefferies

All right. Great.

Jimmy Burnworth

I think we'll get started.

Matthew Stanton, Analyst — Jefferies

My name's Matt Stanton. I'm on the Lifesign School's Diagnostics Team here at Jeffrey's. Happy to have Marvai back with us at the conference again this year. I'm going to hand it over to Raj for some opening comments, and then we'll kick it back over here for some Q&A. So with that, over to you.

Rajesh Asarpota, CFO

Matt, thank you for having us and hosting us. I'll be making forward-looking statements today, so keeping that in mind, like Matt said, a quick overview on the company. So Marwai Life Sciences is a leading provider of critical technologies and products in the mRNA space that enable the development and manufacturing of life-changing therapeutics, vaccines, and diagnostics with a particular focus on nucleic acid production and biologic safety testing. We go to market with, actually, let me step back. We go to market with two Marquis. Brand names of franchises, Trilink and Cygnus, that I'll touch on. So the reporting segments that we have, Cygnus and Trilink, each have different growth dynamics. And to kind of break that down a little bit, Trilink represents about 65% of our revenues. And within Trilink, there are three sub-segments, the flagship being mRNA that consists of... Discovery, that's research and preclinical, GMP, and commercial revenues that will fold into the company starting in 28 and 29. That represents 35% of top line and expected to grow high single digits today, and as you move into commercial, those revenues will add to the growth rate, making it a little bit more around like low double digits. CDMO is our contract manufacturing piece, accounting for less than 10% of revenue, growing at low double digits, and then finishing off with specialty chemistry. That's oligosynthesis consumables, just over 20%, representing low single digits. So really, TriLink is pretty diversified, but a lot of emphasis on high growth and commercial upside within mRNA. Then to round it off, Cygnus is 35% of revenue. This is our bioprocessing tools and analytics business. Cygnus is the gold standard, and it delivers steady, high margins, and we have that in our model growing at mid-single digits. When you think about mRNA drug development, Trilink as a company, you know, we participate in every stage. Nonwithstanding the spies are us, like, you know, bad press on NVIDIA. I think it's still a good analogy, just like NVIDIA doesn't build the AI models. But supplies the compute that every model runs on. Similarly, MARVI doesn't develop the drug, but we supply the leading technologies and services that hundreds of mRNA and genetic medicine programs are built on. So as you look at these phases of drug development from basic research to preclinical, clinical, and commercial, on the basic research side, that's where we seed the market and the start of new programs by supplying research-grade clean cap, mottail, oligos, et cetera, which then kind of scale up in preclinical, where we're also selling clean cap, mottail, and enzymes. And then once you move into clinical, that's where the GMP volume and price step-up is pretty significant. And if you look at our customer base today, we have 50. GMP customers, and each of those customers have two to three programs in the works, so you can get an idea on the shots at goal we have. And as those programs kind of progress through the clinic into commercial, once they get into the commercial space, you're now looking at Five different modalities that I'll talk about, but they range in terms of value from $5 million for a prophylactic vaccine to over $50 million for other modalities per program per year. So a little bit on the phase advancement and how that factors into our revenue per program. If you think about preclinical and then once programs get into the clinic, We probably wait every phase in our long-range plan to include modality risk, because not every program is going to succeed. So as you look at this slide, when a program is in the preclinical stage, The estimated chances of reaching the market are pretty small, but then as you walk through the different phases in the clinic, at phase one, we have a 10% chance. Phase one to two, that goes to 12%, and by the time a program's in phase three, there's a 60% chance that it hits the market. So we take all of that into account, and you can see as you move from phase one to phase three, and when it gets to market, our share of consumables increases in terms of revenue performance. And then this is the money page in terms of how we think about modalities that will provide the commercial upside that I spoke of for 28 and 29. So these five modalities, the formula here is you look at the number of patients that would receive treatment per year times the number of doses administered per year and the mRNA. mRNA within, you know, mRNA per dose. To get to a price realization that... It delivers the expected value per program. So for a prophylactic vaccine, the patients per year is pretty high, but the doses per year is low, similar to what a COVID vaccine would be, and also the mRNA per dose on the low side. So the price realization here, given that it's more batch sizes and large scale, the expected value of that program is pretty low. But then when you advance to personalized medicine and cancer vaccines and mRNA therapeutics, here the amount of doses increases significantly. So think about like a prophylactic vaccine, maybe 35 to 50 micrograms. You're now with a cancer vaccine stepping up to like one milligram that's administered nine, ten times, so it grows significantly larger. And for an mRNA therapeutic, it's even 15 times higher. So when you apply that into the algorithm to think about the price realization and the amount of mRNA per dose, these offer significantly higher value in terms of commercial realization. So again, the takeaway here is $5 million for a vaccine to $50 million per program per year for the other modalities once they get to P. And then the mix of our pipelines, so the current clinical program mix, by phase, we have about 40% programs that are in phase one, 40% in phases one, two, and then 20% in phase two and phase three. Again, 50 GMP customers in 2026, averaging two to three programs, and majority of our clinical pipeline is on the higher modalities that I showed versus the prophylactic vaccine example. And then I'll just finish off by saying, you know, programs in the clinical today use CleanCap, and then the programs that enter the clinic now will not only, you know, incorporate CleanCap and GMP enzymes, but also our new Mottail program, so it has a significant ramp up in terms of the value for programs that are on the come. So with that, I will, if we can get into some Q&A.

Matthew Stanton, Analyst — Jefferies

All right, perfect. That's very helpful. Appreciate that. Maybe just to kick off, you know, being helpful to get the state of a union across kind of biopharma market, you know, you had a good 3Q, raised numbers, talked about, I think, pretty broad-based demand trends. You're seeing, would love to just kind of unpack, you know, are you starting to see some of the funding we've seen in the last few quarters translate into spend at the earlier biotechs, and then also just, you know, the large pharma side? You know, how are they kind of thinking about mRNA, you know, today and kind of the demand across the various customer bases within Biopharma?

Rajesh Asarpota, CFO

Great question. So demand, as you know, we see it as kind of broad-based and improving quite a bit. In the third quarter, we grew our revenue enterprise by 10%, but mRNA itself grew 28%, and Cygnus had 8% growth. So I think on all of those metrics, we significantly have been performing well. If you look at our discovery business in particular, that grew 27% after Q1 growth of, you know, 5%, kind of ramping up to 15%, and then eventually 27% in the third quarter after declining 20% in the year before. So, you know, we think all the COVID. You know, destalking is kind of in the rearview mirror right now, and biopharma is advancing programs, and we are seeing that kind of translate into our GMP results quite nicely. So, you know, customers are coming back to us, one, because we have Mottail, but beyond that, if you look at the full breadth of products now on IVT kits, GMP enzymes, NTPs, it's like a full suite of products, And we are completely seeing that happen. And I would say the other factor that's driving a lot of the growth and discovery is the whole mRNA builder. So as customers come to us for these mRNA construct approaches and they can design what they want, we can provide that. And again, that's been a nice growth driver.

Matthew Stanton, Analyst — Jefferies

Um, maybe as we think about just the durability of those, you know, demand drivers, right? Like you said, you know, MRNA or GMP consumables, very healthy demand. You know, you have a number of new products, ModTail being the big one, but, you know, another, a number that are kind of seeing nice adoption. How do we think about, like, durability, visibility of these as we think about growth into, into 27? And then maybe just a finer point on, you know, the, the GMP COVID related clean cap, what that number was this year, and then will that be in the guide? Or are you going to kind of level set it, you know, kind of orient to the base business?

Rajesh Asarpota, CFO

Yeah, let me take that one first because it's pretty simple. You know, $14 million and change in the first quarter. We are encouraging everybody to take that out of the guide, and that's how we are thinking about it when we talk about that in February, is keep that outside. And if it happens, it's upside. But until we have line of sight into... A commitment, we're not going to put that in our guide. So, you know, you look at the base business, the growth drivers, that's how you should think and model the business, and put COVID aside. So that's part one. In terms of durability, I mean, let's take ModTail as an example. We introduced that last year after getting to 70 customers in Q1 that ramped up to 125. Now it's north of 185. So we see that research traction kind of continue, and then once GMP is introduced at the end of this year, we see a lot of traction in the back half of 27 as it starts to scale up, then that adds an additional dimension to growth on mott tail. And then, you know, again, I'm going to reflect back on the discovery number, which was, like I said, grew 27%. It certainly indicates to us that we are taking a lot of share right now because the market's not growing that fast. We landed a record 70-plus customers in the third quarter. We had 67-ish customers in Q2, which is also a record. So there's no reason why that momentum shouldn't continue. Having said that, you know, two quarters does not make a trend, so as we think about 2027, we want to make sure that it's sustainable, so we'll guide accordingly.

Matthew Stanton, Analyst — Jefferies

Okay. And maybe just on the Cygnus side, you know, I think we've seen kind of solid mid-single-digit growth there. You guys have kind of outlined, you know, potential levers to get that closer to high singles. You have kind of commercial initiatives. You have new product launches, services you're laying in, like. Like, talk about some of those coming into Cygnus as we think about, you know, potential for that to accelerate a bit, you know, into 27 and beyond with those levers you have.

Rajesh Asarpota, CFO

Yeah, some of those we've already kind of made moves on. So we have, we've onboarded a new leader in China to, again, work with distributors and customers directly and smooth some of that volatility we've seen in recent, you know, quarters. We're doing something similar in the United States. So today we have a lot of business development that drives revenue, but it's not the same as having You know, a direct commercial presence, so we are looking to do that. You know, on the innovation side, on Mach-V, we had an additional SV40 kit that was introduced, along with the PRISM-A-GO. I always have trouble with that, but mix-a-go kit that is also, you know, continuing to add to the innovation. I think, and then beyond that, you know, we talked a little bit about the services business. We invested in a mass spec machine last, an additional mass spec machine last year. It's slightly longer term, but we think that has growth potential as well. So you go from mid-single digits to adding a couple of points of growth through these initiatives.

Matthew Stanton, Analyst — Jefferies

And maybe just kind of on that, you know, topic, just NPIs more broadly, I think a lot of focus is on, you know, ModTail and the launch there, rightfully so. But, you know, you talked about the enzymes and the mRNA builder, Mix & Go, new Mach-V kit, right? You know, as we think about kind of layering those various launches on top of each other, none huge in their own right, but you kind of stack them together. I mean, is there opportunity, as we think about ability to outgrow the market, you know, you stack those together and maybe you do have a few points of, you know, growth. As we look out, kind of over the midterm?

Rajesh Asarpota, CFO

Yeah, yeah, for sure. Kind of like some of the bioprox, you know, bioprox. Yeah, for sure. I think on, like we said, Mottail definitely is getting traction, and Mottail kind of mimics what clean cap did, like research used first, then, you know, a year later, it starts to move into the GMP, and then as, you know. As trials progress, you get a broader adoption on clean cap, and Mottail is going to follow a similar kind of arc or pathway. I think beyond that, as I explained, like... You know, Trilink is now a very different company than it used to be. It used to be known as a clean cap company, but now with the breadth of products we have and the way customers approach us to build their mRNA constructs, we are giving them the whole suite of products. So to your point on those NPIs, and as we continue to innovate and offer design services and products that they want, it can definitely be a needle mover in terms of shifting growth. That outbases the market.

Matthew Stanton, Analyst — Jefferies

Okay, and maybe on ModTail and maybe using CleanCap as some type of, you know, an analogy, right? You talked about. Launch last year went really well. I think you guys said you had 500 or so of revenue last year in only a few months, you know, continuing to add customers. I assume that's kind of run rating at a nice clip. I mean, is there a scenario where we're talking about, you know, Motel, especially after GMP rolled out, you know, this is a tens of millions of dollar product, you know, as we look out a few years, not unlike CleanCap, which followed that trajectory even before, you know, 2020 and kind of the COVID dynamics.

Rajesh Asarpota, CFO

Yeah, my commercial guy and the modeler will definitely address that. So, Jimmy's deep into it.

Jimmy Burnworth

The short answer is I think we do see Modtail being even larger than clean cap in a lot of ways. And the way we sell it, we're already selling at a premium to clean cap. And it's helping us not just sell more clean cap, it's also helping us sell the full mRNA construct. And our customers are seeing incredible value because it's delivering... Higher protein expression, higher level of durability, so it's leading to repeat purchases and customers' programs advancing, and that's where it can get really exciting, where it can go from a purchase that's tens of thousands to hundreds of thousands, and then once it reaches the clinic, you're looking at customers that are going to buy four or five times that in terms of volume. So we've seen the traction, and it's going to be significant and provide quite a bit of growth into next year.

Matthew Stanton, Analyst — Jefferies

Okay. And then maybe just on the demand profile, right, you have clean cap, this kind of plan on the other side of the molecule. I imagine a lot's from existing customers that know clean cap, know TriLink, but there's other enzymatic capping technologies or other capping technologies out there which could utilize this. So maybe just talk about demand profile to date, as well as kind of opportunity going forward as you educate those other kind of cappings.

Rajesh Asarpota, CFO

Yeah, definitely. So Martail is agnostic to cappings, so enzymatic customers can also leverage Martail.

Jimmy Burnworth

I would just say, like, when we analyze the 70 new or greater than 70 mRNA discovery customers, a big portion of that was coming from ModTail. So it's not only supporting existing customers, but we're adding new customers, which is new programs along the way that's driving the results. And it's pretty broad-based in terms of, you know, the customer.

Rajesh Asarpota, CFO

I guess the point I was going to make, Jimmy, and maybe you should just address the attachment rate.

Jimmy Burnworth

Yeah, so when we sell ModTail greater than 90% of the time, we sell it along with clean cap or other reagents as well.

Matthew Stanton, Analyst — Jefferies

And maybe just remind us, you have GMP coming in 27. It sounds like there's demand for that. Just talk about the rollout of GMP, how that kind of looks as we think about cadence of that rollout and customers starting to utilize it into 27. Sounds like more back half, but just kind of any finer point on the GMP rollout.

Rajesh Asarpota, CFO

Yeah, so the launch is on time, so that's going to happen, you know, with the next four to four weeks or so that are four to six weeks that are left in the year. And then as customers start to look at their qualification and how they're going to kind of progress, we think by the second half of 27 is when you would start to see dollars in terms of, you know, being contributed from Martial GMP. Okay.

Matthew Stanton, Analyst — Jefferies

Maybe shifting gears to China, I think historically, TriLink's been relatively under-indexed there, especially relative to Cygnus. You are seemingly on the cusp of entering or potentially entering that market more meaningfully. You've made some moves on the IP front. I think you've hired or are about to hire a head of commercial to kind of approach that. But maybe just talk about how the rollout or entrance of TriLink in China looks and maybe some of the kind of demand signals or conversations you have with folks that give you kind of confidence that this is the right time and there's demand on the other side.

Rajesh Asarpota, CFO

Yeah, big picture, there's over 800 companies. Doing mRNA and gRNA, right? And then about roughly 150 to 160 of those companies are in China. So it's a pretty meaningful number. And as you think about China as a greenfield opportunity, because today we've got nothing in China for TriLink, but as these companies, you know, progress through their trials and they... You know, want to engage with global pharma or want to enter into the U.S. market. I think there's two things. One, those patents that we just talked about. Those companies, if they have aspirations, they want to be on the right side of IP. So having those patents protects us in that regard. Like you said, we've already onboarded a leader in China to develop distributor relationships and partnerships to make sure that once we get started, that we've got. The right amount of, you know, feet on the street and the right partnerships. And then, you know, I think beyond that, we, you know, once you start to have those feet on the street and once you start to make some inroads, I think the opportunity is huge. It just won't happen a lot next year, but beyond that, we should see a pretty big opportunity.

Matthew Stanton, Analyst — Jefferies

Okay.

Rajesh Asarpota, CFO

That's helpful.

Matthew Stanton, Analyst — Jefferies

Maybe going back to the mid- to long-term targets you laid out on one of the first slides earlier, I think the growth side is pretty clear. Just on the margin side, you didn't put out formal margin targets, but you guys have done a really good job on the cost side, right? We're back to this kind of 70% incremental margin story. How do we think about... The margin trajectory within that kind of mid-term, you know, framework, especially given very healthy margins at Cygnus, you know, trialing continues to improve. Like, is there a pathway to, you know, mid-20s or better type, you know, EBITDA margins within the construct you have at the top line given where incremental shakeout for this business?

Rajesh Asarpota, CFO

Yeah, I would say actually that that is conservative because, again, if you just... Look at our model that's been reset, and what we're seeing is 70% of every incremental revenue dollar or 70% falls to the bottom line. So as you think about the growth that we're seeing within Discovery and GMP, and, you know, Cygnus is steady, but if that also, in terms of the mix, is there, you're going to see those margins get significantly higher. Again, for $27, we're not... You know, giving guidance because we just, you know, but long term, that's how you would need to think about it is in terms of the model, what that growth looks like. And like we said before, we can flow hundreds of millions of dollars of revenue to the P&L without increasing our operating expenses or CapEx.

Matthew Stanton, Analyst — Jefferies

Okay. And maybe just in that vein, gross margins, I think you guys have taken up the guidance there twice this year, over 1,600 basis points of expansion this year, so very meaningful progress. As we think about that longer-term construct, is there scope and visibility to push gross margins above 60% as we think about the opportunity there?

Rajesh Asarpota, CFO

Yeah, I'll give that to Jimmy because he's got initiatives that he's thriving to make that even better.

Jimmy Burnworth

Yeah, no, I mean, we're doing a lot to improve margins, and really the number one driver of that improvement is going to be the drop-through that Raj mentioned. So every dollar at a minimum is going to drop through 70% to EBITDA, and it's probably, you know, equivalent to that or higher at gross margin. But beyond that, we continue to define initiatives. I mean, AI is a big one for us. We've rolled that out across the company and have gotten significant adoption. We've collected hundreds of use cases now, and we think that'll just overall help improve manufacturing efficiency and continue to drive some margin. So I think being north of 60% in the near term is . It's very doable.

Matthew Stanton, Analyst — Jefferies

Okay. And maybe just on that AI deployment, hundreds of use cases sounds encouraging. Are there one or two or three that are kind of really sticking out in terms of optimizing kind of production today or in the near term versus what might be more longer term? Like, how do you kind of think about what's happening?

Jimmy Burnworth

Yeah, I think the biggest thing, if you think about TriLink, we have decades of MRNA experience and data that's sitting around. And so for the team, they've spent a lot of time collecting that data and figuring out how to feed it into models. We have both, you know, off-the-shelf models, but also we have, you know, proprietary internal models that were purchased a year and a half ago through our Oficina acquisition. And so we're in a position to really drive value in AI, not just because of the technology that's currently out there to everyone, but also the data that we have that nobody else has.

Matthew Stanton, Analyst — Jefferies

And that sounds like it's a potential revenue opportunity if you're packaging or selling that data?

Jimmy Burnworth

Exactly. And right now, we're already offering, you know, to an extent, we're already offering some of that service through our MR&A AI builder, and that's already getting significant adoption, but we can further roll out more and more capabilities because of the data set we have.

Rajesh Asarpota, CFO

Matt, but even on the commercial side, if you think about the tools that we have available now through AI, like Jimmy said, the data is so extensive, that account planning is so accurate, so precise. The insights we have into each of our customers is as good outside the company as those individuals inside the company would have. So it just gives us a lot of leverage versus cold calling a customer. You've got really good account planning tools.

Matthew Stanton, Analyst — Jefferies

Okay. Well, with that, we're out of time. Appreciate it both. Thank you.

Rajesh Asarpota, CFO

Thank you.